How should a 36-year-old nulligravid hypertensive woman with acute‑on‑chronic heavy menstrual bleeding due to a 2 cm submucosal leiomyoma, anemia (hemoglobin 88 g/L), and mildly prolonged coagulation studies be managed, given her desire for future pregnancy?

Management of Acute-on-Chronic Heavy Menstrual Bleeding from Submucosal Fibroid

Your management plan is appropriate and well-structured: immediate hemodynamic stabilization with blood transfusion, combined hormonal therapy (medroxyprogesterone) plus tranexamic acid, followed by hysteroscopic myomectomy once anemia is corrected—this is the standard of care for a 2 cm submucosal fibroid in a woman desiring future pregnancy 1.

Critical Initial Considerations

Address the Losartan Immediately

Stop losartan now and switch to a pregnancy-compatible antihypertensive (methyldopa, labetalol, or nifedipine). Losartan is an angiotensin receptor blocker that is absolutely contraindicated in pregnancy due to fetal renal toxicity and death 2. Since she desires pregnancy and you're about to do a pregnancy test, this medication change cannot wait.

Investigate the Coagulopathy

The mildly prolonged PT/aPTT requires urgent clarification before any surgical intervention. While this could represent consumptive coagulopathy from severe anemia and massive bleeding, you must rule out an underlying bleeding disorder 3. Approximately 13-20% of women with heavy menstrual bleeding have an undiagnosed bleeding disorder. Order:

• Von Willebrand factor antigen and activity
• Factor VIII and IX levels
• Platelet function studies if available
• Repeat PT/aPTT after transfusion to see if it corrects

Acute Phase Management (Current—Next 48-72 Hours)

Hemodynamic Stabilization

Your plan for blood transfusion is correct. With hemoglobin of 88 g/L (8.8 g/dL) and active bleeding requiring 2 adult diapers daily, she needs:

• Packed red blood cells to target hemoglobin >100 g/L before surgery
• IV iron supplementation (iron sucrose or ferric carboxymaltose) in addition to oral iron for faster repletion 4
• Continuous monitoring for cardiac complications—severe anemia can cause reversible myocardial dysfunction 5

Acute Bleeding Control

Your combination therapy is evidence-based 6, 4:

Tranexamic acid: 1,300 mg orally three times daily or 1 gram IV every 6-8 hours during active bleeding. This is a first-line antifibrinolytic that reduces menstrual blood loss by 40-50% 1, 4.

High-dose progestin: Medroxyprogesterone acetate 20 mg three times daily for 7 days, then taper to 10-20 mg daily. This stabilizes the endometrium rapidly 6, 4. Alternative regimens include:

• Combined oral contraceptives (monophasic) 1 pill three times daily for 7 days if not contraindicated by her hypertension
• However, given her hypertension (130/70, controlled but present), progestin-only is safer

Bridging Phase (Week 2-8)

After acute bleeding stops, continue progestin-based therapy to maintain endometrial suppression while correcting anemia and preparing for surgery 6. Options include:

• Medroxyprogesterone 10-20 mg daily continuously
• Norethindrone acetate 5-10 mg daily
• Continue tranexamic acid during any breakthrough bleeding

Do NOT place a levonorgestrel IUD during this phase—it is a long-term maintenance option, not a bridging therapy, and insertion during active bleeding with severe anemia carries unnecessary risks 6.

Target hemoglobin >110 g/L and ferritin >50 ng/mL before proceeding to surgery 7.

Definitive Surgical Management

Hysteroscopic Myomectomy Timing

Wait 6-8 weeks after bleeding control and anemia correction before surgery 1, 8. This allows:

• Hemoglobin restoration to safe surgical levels
• Endometrial healing and thinning
• Clarification of coagulation status
• Safer anesthetic risk

Pre-operative Imaging

Your plan for saline infusion sonography (SIS) or diagnostic hysteroscopy with endometrial biopsy is appropriate 8. This will:

• Confirm the 2 cm submucosal fibroid is FIGO type 0,1, or 2
• Rule out endometrial pathology (mandatory given her age and bleeding pattern)
• Map any additional fibroids

Hysteroscopic Myomectomy Technique

Hysteroscopic myomectomy is the procedure of choice for submucosal fibroids <5 cm in women desiring pregnancy 1. The 2 cm posterior fundal location is ideal for hysteroscopic approach. Advantages include:

• Shorter hospitalization and recovery compared to laparoscopic/open approaches
• Equivalent symptom improvement and quality of life outcomes 1
• Preservation of uterine integrity for future pregnancy 8

Critical Pitfall to Avoid

Do NOT use GnRH agonists or antagonists (relugolix, leuprolide) for this patient 9. While these agents shrink fibroids and are commonly used pre-operatively, there is specific evidence that FIGO type 0 pedunculated submucosal fibroids treated with relugolix can cause severe hemorrhage requiring emergency surgery and transfusion 9. Your fibroid is described as "intracavitary" which suggests it may be type 0. Even if it's type 1 or 2, the risk-benefit ratio doesn't favor GnRH therapy when she's already severely anemic and you're planning definitive surgery in 6-8 weeks.

Fertility Counseling

After hysteroscopic myomectomy, counsel her that:

• Pregnancy success rates are good for submucosal fibroids treated hysteroscopically 8
• Wait 2-3 menstrual cycles before attempting conception to allow uterine healing
• She will need close obstetric monitoring given her hypertension history (increased preeclampsia risk) 2
• Ensure she's on pregnancy-safe antihypertensives before conception

Monitoring Plan

• Daily hemoglobin checks until stable and rising
• Repeat coagulation studies after transfusion
• Weekly hemoglobin and ferritin during bridging phase
• Assess bleeding pattern on progestin therapy
• Repeat pelvic ultrasound at 6 weeks to confirm fibroid stability

Your overall approach demonstrates excellent clinical judgment—the key modifications are switching the antihypertensive immediately, investigating the coagulopathy thoroughly, avoiding GnRH therapy, and ensuring adequate time for hematologic recovery before surgery 1, 6, 4.